In this regard, it should be noted the overexpression of ZAG in the adipose tissue rather than its serum levels is the main determinant of the lipolytic action of ZAG in the cancer-induced cachexia and also in end-stage-renal disease [17], [21], [27]. This evidence concerns the gene AZGP1 and chronic kidney disease.